Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma

Genes Chromosomes and Cancer

Volumn 49, Issue 1, 2010, Pages 17-27

  Trakhtenbrot, Luba ^a   Hardan, Izhar ^b   Koren Michowitz, Maya ^b   Oren, Shirley ^b   Yshoev, Galina ^b   Rechavi, Gideon ^b   Nagler, Arnon ^b   Amariglio, Ninette ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN HEAVY CHAIN;

ARTICLE; CELL STRUCTURE; CHROMOSOME 11Q; CHROMOSOME 13; CHROMOSOME 13Q; CHROMOSOME 14; CHROMOSOME 14Q; CHROMOSOME ARM; CHROMOSOME BAND; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION; CHROMOSOME VARIANT; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; HUMAN; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

CELL SHAPE; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 14; CYCLIN D1; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 74949131600     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20716     Document Type: Article

References (34)

1. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R. 2002. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185-2191.
2. Bergsagel PL. 2003. Prognostic factors in multiple myeloma: It's in the genes. Clin Cancer Res 9:533-534.
3. Bergsagel PL, Kuehl WM. 2005. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338.
4. Chen L, Xu J, Li W, Qiu H, Zhu Y, Zhang Y, Duan L, Qian S, Lu H. 2007. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol 29:116-120.
5. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Dávila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. 2005. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106:2156-2161.
6. Christensen JH, Abildgaard N, Plesner T, Nibe A, Nielsen O, Sørensen AG, Kerndrup GB. 2007. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: Analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet 174:89-99.
7. Cohen N, Novikov I, Hardan I, Esa A,. Brok-Simoni F, Amariglio N, Rechavi G, Ben-Bassat I, Trakhtenbrot L. 2000. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 123:102-108.
8. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, Benner A, Raab MS, Theil AC, Moos M, Goldschmidt H, Bartram CR, Jauch A. 2005. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44:194-203.
9. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. 2000. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010.
10. Fancon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY. 2001. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566-1571.
11. Fonseca R, Oken MM, Greipp PR. 2001. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 98:1271-1272.
12. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. 2002a. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An eastern cooperative oncology group study. Cancer Res 62:715-720.
13. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. 2002b. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99:3735-3741.
14. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Davila R, Gonzalez-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. 2003. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2563-2567.
15. Hardan I, Rothman R, Gelibter A, Cohen N, Shimoni A, Sokolovsky M, Reichart M, Ishoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. 2004. Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis. Exp Hematol 32:254-260.
16. Huang SY, Yao M, Tang JL, Tsay W, Lee FV, Liu MC, Wang CH, Chen YC, Shen MC, Tien HF. 2005. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol 16:1530-1538.
17. Janssen JW, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E. 2000. Concurrent activation of a novel putative transforming gene, MYEOV, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood 95:2691-2698.
18. Kaufmann H, Kromer E, Nosslinger T, Weltermann A, Ackermann J, Reisner R, Bernhart M, Drach J. 2003. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol 71:179-183.
19. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM. 2003. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101:1520-1529.
20. Keats JJ, Reiman T, Belch AR, Pilarski LM. 2006. Ten years and counting: So what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 47:2289-300.
21. Koren-Michowitz M, Hardan I, Berghoff J, Yshoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. 2007. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: A combined morphology and I-FISH analysis. Cancer Lett 255:307-314.
22. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H. 2002. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100:579-583.
23. Pratt G. 2002. Molecular aspects of multiple myeloma. J Clin Pathol 55:273-283.
24. Remstein ED, Kurtin PJ, Buño I, Bailey RJ, Proffitt J, Wyatt WA, Hanson CA, Dewald GW. 2000. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 110:856-862.
25. Ronchetti D, Finelli P, Richelda R, Baldini L, Rocchi M, Viggiano Ll, Cuneo Al, Bogni Sl, Fabris Sl, Lombardi L, Maiolo AT, Neri A. 1999. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93:1330-1337.
26. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L. 2002. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (DuetTM) combined morphological and cytological analysis. Leukemia 16:413-1418.
27. Slovak ML, Bedell V, Pagel K, Chang KL, Smith D, Somlo G. 2005. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: Phenotype/genotype fluorescence in situ hybridization. Cancer Genet Cytogenet 158:99-109.
28. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. 2001. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2238.
29. Smadja NV, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S, Taillemite JL, Bastard C. 2003. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38:234-239.
30. Takimoto M, Ogawa K, Kato Y, Saito T, Suzuki T, Irei M, Shibuya Y, Suzuki Y, Kato M, Inoue Y, Takahashi M, Sugimori H, Miura I. 2008. Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: A high incidence of 11q13/CCND1 and 16q23/MAF. Int J Hematol 87:260-265.
31. Trakhtenbrot L, Reichart M, Shimoni A. 2002. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (DuetTM) combined morphological and cytological analysis. Leukemia 16:1419-1422.
32. Wlodarska I, Matthews C, Veyt E, Pospisilova H, Catherwood MA, Poulsen TS, Vanhentenrijk V, Ibbotson R, Vandenberghe P, Morris TC, Alexander HD. 2007. Telomeric IGH losses detectable by fluorescence in situ hybridization in chronic lymphocytic leukemia reflect somatic VH recombination events. J Mol Diagn 9:47-54.
33. Zelenetz AD, Cleary ML, Levy R. 1993. A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma. Genes Chromosomes Cancer 6:140-150.
34. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Krömer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. 2000. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925-1930.